Total Valuation
Addex Therapeutics has a market cap or net worth of CHF2.76M. The enterprise value is $4.26M.
Market CapCHF2.76M
Enterprise Value$4.26M
Share Statistics
Addex Therapeutics has 218,654,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding218,654,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Addex Therapeutics’s return on equity (ROE) is -1.41 and return on invested capital (ROIC) is -54.47%.
Return on Equity (ROE)-1.41
Return on Assets (ROA)-1.06
Return on Invested Capital (ROIC)-54.47%
Return on Capital Employed (ROCE)-0.55
Revenue Per Employee57.67K
Profits Per Employee-2.28M
Employee Count3
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Addex Therapeutics is ―. Addex Therapeutics’s PEG ratio is 0.00503.
PE Ratio―
PS Ratio35.91
PB Ratio1.30
Price to FCF-2.86
Price to Operating Cash Flow-1.71
PEG Ratio0.00503
Income Statement
In the last 12 months, Addex Therapeutics had revenue of 173.00K and earned -6.73M in profits. Earnings per share was -0.06.
Revenue173.00K
Gross Profit164.39K
Operating Income-2.81M
Pretax Income-6.84M
Net Income-6.73M
EBITDA-2.81M
Earnings Per Share (EPS)-0.06
Cash Flow
In the last 12 months, operating cash flow was -2.39M and capital expenditures -5.00, giving a free cash flow of -2.39M billion.
Operating Cash Flow-2.39M
Free Cash Flow-2.39M
Free Cash Flow per Share-0.01
Dividends & Yields
Addex Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.10
52-Week Price Change-62.50%
50-Day Moving Average0.03
200-Day Moving Average0.04
Relative Strength Index (RSI)17.55
Average Volume (3m)48.63K
Important Dates
Addex Therapeutics upcoming earnings date is Nov 9, 2026, TBA (Confirmed).
Last Earnings DateSep 28, 2026
Next Earnings DateNov 9, 2026
Ex-Dividend Date―
Financial Position
Addex Therapeutics as a current ratio of 1.40, with Debt / Equity ratio of 4.07%
Current Ratio1.40
Quick Ratio1.40
Debt to Market Cap0.00
Net Debt to EBITDA0.57
Interest Coverage Ratio-175.94
Taxes
In the past 12 months, Addex Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Addex Therapeutics EV to EBITDA ratio is -1.64, with an EV/FCF ratio of -2.12.
EV to Sales26.64
EV to EBITDA-1.64
EV to Free Cash Flow-2.12
EV to Operating Cash Flow-2.12
Balance Sheet
Addex Therapeutics has CHF767.33K in cash and marketable securities with CHF77.50K in debt, giving a net cash position of CHF689.83K billion.
Cash & Marketable SecuritiesCHF767.33K
Total DebtCHF77.50K
Net CashCHF689.83K
Net Cash Per Share<CHF0.01
Tangible Book Value Per ShareCHF0.04
Margins
Gross margin is 41.19%, with operating margin of -1627.17%, and net profit margin of -3889.60%.
Gross Margin41.19%
Operating Margin-1627.17%
Pretax Margin-3955.25%
Net Profit Margin-3889.60%
EBITDA Margin-1627.17%
EBIT Margin-1627.17%
Analyst Forecast
The average price target for Addex Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-50.34%
EPS Growth Forecast4.75%